As Biotechnology companies, VistaGen Therapeutics Inc. (NASDAQ:VTGN) and Gemphire Therapeutics Inc. (NASDAQ:GEMP) are our subject to compare. And more specifically their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics Inc.	N/A	0.00	24.06M	-0.93	0.00
Gemphire Therapeutics Inc.	N/A	0.00	23.64M	-2.11	0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of VistaGen Therapeutics Inc. and Gemphire Therapeutics Inc.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics Inc.	0.00%	-608.9%	-267.7%
Gemphire Therapeutics Inc.	0.00%	-211%	-99.4%

Liquidity

3.6 and 3.6 are the respective Current Ratio and a Quick Ratio of VistaGen Therapeutics Inc. Its rival Gemphire Therapeutics Inc.’s Current and Quick Ratios are 3.3 and 3.3 respectively. VistaGen Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Gemphire Therapeutics Inc.

Institutional and Insider Ownership

VistaGen Therapeutics Inc. and Gemphire Therapeutics Inc. has shares owned by institutional investors as follows: 18% and 26.1%. Insiders owned 0.1% of VistaGen Therapeutics Inc. shares. Insiders Competitively, owned 23.61% of Gemphire Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
VistaGen Therapeutics Inc.	-16.18%	-30.91%	-33.33%	-23.49%	-3.39%	-24%
Gemphire Therapeutics Inc.	15.83%	29.91%	16.81%	-4.14%	-80.14%	71.63%

For the past year VistaGen Therapeutics Inc. has -24% weaker performance while Gemphire Therapeutics Inc. has 71.63% stronger performance.

Summary

Gemphire Therapeutics Inc. beats on 4 of the 6 factors VistaGen Therapeutics Inc.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH). It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. The company is headquartered in Livonia, Michigan.